ATE422358T1 - Kombinationstherapie mittels reovirus und anti- antireovirus antikörpern zur behandlung von ras- vermittelten, proliferativen erkrankungen - Google Patents
Kombinationstherapie mittels reovirus und anti- antireovirus antikörpern zur behandlung von ras- vermittelten, proliferativen erkrankungenInfo
- Publication number
- ATE422358T1 ATE422358T1 AT01953727T AT01953727T ATE422358T1 AT E422358 T1 ATE422358 T1 AT E422358T1 AT 01953727 T AT01953727 T AT 01953727T AT 01953727 T AT01953727 T AT 01953727T AT E422358 T1 ATE422358 T1 AT E422358T1
- Authority
- AT
- Austria
- Prior art keywords
- reovirus
- ras
- mediated
- treatment
- combination therapy
- Prior art date
Links
- 241000702263 Reovirus sp. Species 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/765—Reovirus; Rotavirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4216—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/948—Microorganisms using viruses or cell lines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/636,597 US6565831B1 (en) | 1999-02-24 | 2000-08-10 | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE422358T1 true ATE422358T1 (de) | 2009-02-15 |
Family
ID=24552555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01953727T ATE422358T1 (de) | 2000-08-10 | 2001-07-20 | Kombinationstherapie mittels reovirus und anti- antireovirus antikörpern zur behandlung von ras- vermittelten, proliferativen erkrankungen |
Country Status (15)
Country | Link |
---|---|
US (4) | US6565831B1 (de) |
EP (3) | EP2027866A1 (de) |
JP (1) | JP2004505924A (de) |
AR (1) | AR029839A1 (de) |
AT (1) | ATE422358T1 (de) |
AU (2) | AU7621801A (de) |
BR (1) | BR0113128A (de) |
CA (1) | CA2415750C (de) |
DE (1) | DE60137631D1 (de) |
ES (1) | ES2317921T3 (de) |
IL (2) | IL153846A0 (de) |
MX (2) | MXPA03000859A (de) |
NZ (1) | NZ523509A (de) |
WO (1) | WO2002011742A2 (de) |
ZA (1) | ZA200300411B (de) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6110461A (en) * | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
US6565831B1 (en) * | 1999-02-24 | 2003-05-20 | Oncolytics Biotech Inc. | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
US6136307A (en) * | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
US6620382B1 (en) | 1998-05-22 | 2003-09-16 | Biopheresis Technologies, Llc. | Method and compositions for treatment of cancers |
US8197430B1 (en) | 1998-05-22 | 2012-06-12 | Biopheresis Technologies, Inc. | Method and system to remove cytokine inhibitor in patients |
US6379708B1 (en) * | 1999-11-20 | 2002-04-30 | Cytologic, Llc | Method for enhancing immune responses in mammals |
EP1332366B1 (de) * | 2000-11-09 | 2010-06-30 | Oncolytics Biotech, Inc. | Verfahren zur Beurteilung von zellulären proliferativen Erkrankungen |
AR035227A1 (es) * | 2001-02-20 | 2004-05-05 | Oncolytics Biotech Inc | Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus |
AU2002335667A1 (en) * | 2001-08-03 | 2003-02-17 | Board Of Regents, The University Of Texas System | Modified reoviral therapy |
US20040115170A1 (en) * | 2001-11-30 | 2004-06-17 | Brown Earl Garnet | Oncolytic virus |
WO2003094939A1 (en) * | 2002-05-10 | 2003-11-20 | Oncolytics Biotech Inc. | Sensitization of neoplastic cells to radiation therapy with oncolytic viruses |
US7163678B2 (en) * | 2002-11-07 | 2007-01-16 | Oncolytics Biotech Inc. | Reovirus for the treatment of ral-mediated cellular proliferative disorders |
CN1780556A (zh) * | 2003-04-25 | 2006-05-31 | 威尔斯达特生物制剂公司 | 利用治疗性病毒治疗肝细胞癌 |
WO2005002607A2 (en) * | 2003-07-07 | 2005-01-13 | Oncolytics Biotech Inc. | Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac |
US7939090B2 (en) | 2003-10-21 | 2011-05-10 | Cedars-Sinai Medical Center | System and method for the treatment of cancer, including cancers of the central nervous system |
US20050137152A1 (en) * | 2003-12-19 | 2005-06-23 | Danny Cheung | Reovirus for the prevention of neoplasia |
US10668119B2 (en) | 2005-08-01 | 2020-06-02 | Virocure, Inc. | Attenuated reovirus |
US10260049B2 (en) * | 2005-08-01 | 2019-04-16 | Virocure, Inc. | Attenuated reovirus |
US20070065514A1 (en) * | 2005-09-22 | 2007-03-22 | Howell Mark D | Method for enhancing immune responses in mammals |
ES2672627T3 (es) * | 2006-02-02 | 2018-06-15 | Novartis Ag | Tratamiento de la esclerosis tuberosa |
AU2011205053B2 (en) * | 2006-02-02 | 2013-02-07 | Novartis Ag | Tuberous Sclerosis treatment |
BRPI0707654A2 (pt) * | 2006-02-13 | 2011-05-10 | Oncolytics Biotech Inc | mÉtodo para tratar ou melhorar um tumor sàlido em um indivÍduo |
US20080075690A1 (en) * | 2006-09-22 | 2008-03-27 | Mark Douglas Howell | Method for enhancing immune responses in mammals |
CN103710359A (zh) | 2007-03-12 | 2014-04-09 | 昂科利蒂克斯生物科技公司 | 具有修饰的序列的呼肠孤病毒 |
US10369171B2 (en) | 2007-03-13 | 2019-08-06 | Virocure, Inc. | Attenuated reoviruses for selection of cell populations |
TW200909581A (en) * | 2007-05-21 | 2009-03-01 | Oncolytics Biotech Inc | Mutant reoviruses and methods of making and using |
WO2009052617A1 (en) * | 2007-10-22 | 2009-04-30 | Oncolytics Biotech Inc. | Treatment regime for proliferative disorders |
WO2009135614A2 (en) * | 2008-05-09 | 2009-11-12 | Bayer Schering Pharma Aktiengesellschaft | Use of a virus regimen for the treatment of diseases |
EP2296678A4 (de) * | 2008-05-27 | 2012-03-21 | Oncolytics Biotech Inc | Modulation des interstitiellen drucks sowie onkolytische virenfreisetzung und -verteilung |
US8470312B2 (en) * | 2008-05-27 | 2013-06-25 | Oncolytics Biotech, Inc. | Abrogating proinflammatory cytokine production during oncolytic reovirus therapy |
US20120064143A1 (en) | 2008-11-11 | 2012-03-15 | The Board Of Regents Of The University Of Texas System | Inhibition of mammalian target of rapamycin |
WO2010105347A1 (en) | 2009-03-16 | 2010-09-23 | Mcmaster University | Vaccination methods |
US10391059B2 (en) | 2009-11-11 | 2019-08-27 | Rapamycin Holdings, Inc. | Oral rapamycin nanoparticle preparations and use |
US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
CN103347535B (zh) * | 2010-12-02 | 2015-11-25 | 昂科利蒂克斯生物科技公司 | 液体病毒制剂 |
CA2901501C (en) | 2013-02-21 | 2023-03-07 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Vaccine composition |
US20160030401A1 (en) | 2013-03-13 | 2016-02-04 | The Board Of Regents Of The University Of Texas System | Use of mtor inhibitors for prevention of intestinal polyp growth and cancer |
CA2930629A1 (en) | 2013-11-15 | 2015-05-21 | Oncolytics Biotech Inc. | Oncolytic viruses and increased cancer treatment regimens |
US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4108983A (en) | 1976-06-01 | 1978-08-22 | The Wistar Institute | Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
WO1990009441A1 (en) | 1989-02-01 | 1990-08-23 | The General Hospital Corporation | Herpes simplex virus type i expression vector |
AU5275290A (en) | 1989-04-11 | 1990-11-05 | Board Of Regents, The University Of Texas System | Antitumor preparation obtained following oncolysate treatment |
CA2039921A1 (en) | 1990-04-16 | 1991-10-17 | Xandra O. Breakefield | Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication |
CA2051289C (en) | 1990-09-14 | 2002-11-26 | Robert L. Martuza | Viral mediated destruction of neoplastic cells |
CA2152941C (en) | 1993-02-16 | 2003-04-22 | Francis Mccormick | Cytopathic viruses for therapy and prophylaxis of neoplasia |
US5853716A (en) | 1995-07-28 | 1998-12-29 | Yale University | Genetically engineered chimeric viruses for the treatment of diseases associated with viral transactivators |
TW349948B (en) | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
JP2000511539A (ja) | 1996-05-31 | 2000-09-05 | ジェネティック・セラピー・インコーポレイテッド | 負の選択マーカーをコード化するポリヌクレオチドを含むt細胞による対宿主性移植片病の予防 |
WO1998008541A1 (en) | 1996-08-30 | 1998-03-05 | Genzyme Corporation | Inhibition of primary and/or secondary immune response to repeat adenoviral vector administration using cd40l specific antibodies |
US6565831B1 (en) * | 1999-02-24 | 2003-05-20 | Oncolytics Biotech Inc. | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
US6136307A (en) * | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
US6110461A (en) | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
HUP0003911A3 (en) | 1997-10-09 | 2007-11-28 | Pro Virus | Treatment of neoplasms with viruses |
US6406861B1 (en) | 1998-10-07 | 2002-06-18 | Cell Genesys, Inc. | Methods of enhancing effectiveness of therapeutic viral immunogenic agent administration |
US6464976B1 (en) | 1999-09-07 | 2002-10-15 | Canji, Inc. | Methods and compositions for reducing immune response |
WO2003094939A1 (en) * | 2002-05-10 | 2003-11-20 | Oncolytics Biotech Inc. | Sensitization of neoplastic cells to radiation therapy with oncolytic viruses |
-
2000
- 2000-08-10 US US09/636,597 patent/US6565831B1/en not_active Expired - Lifetime
-
2001
- 2001-07-17 AR ARP010103413A patent/AR029839A1/es unknown
- 2001-07-20 MX MXPA03000859A patent/MXPA03000859A/es active IP Right Grant
- 2001-07-20 EP EP08006359A patent/EP2027866A1/de not_active Withdrawn
- 2001-07-20 WO PCT/CA2001/001055 patent/WO2002011742A2/en active IP Right Grant
- 2001-07-20 CA CA002415750A patent/CA2415750C/en not_active Expired - Lifetime
- 2001-07-20 ES ES01953727T patent/ES2317921T3/es not_active Expired - Lifetime
- 2001-07-20 ZA ZA200300411A patent/ZA200300411B/xx unknown
- 2001-07-20 EP EP01953727A patent/EP1309334B1/de not_active Expired - Lifetime
- 2001-07-20 JP JP2002517077A patent/JP2004505924A/ja active Pending
- 2001-07-20 BR BR0113128-1A patent/BR0113128A/pt not_active IP Right Cessation
- 2001-07-20 AU AU7621801A patent/AU7621801A/xx active Pending
- 2001-07-20 EP EP08006362A patent/EP2016948A3/de not_active Withdrawn
- 2001-07-20 NZ NZ523509A patent/NZ523509A/en unknown
- 2001-07-20 AT AT01953727T patent/ATE422358T1/de not_active IP Right Cessation
- 2001-07-20 MX MX2014008295A patent/MX358055B/es unknown
- 2001-07-20 DE DE60137631T patent/DE60137631D1/de not_active Expired - Lifetime
- 2001-07-20 IL IL15384601A patent/IL153846A0/xx unknown
- 2001-07-20 AU AU2001276218A patent/AU2001276218B8/en not_active Expired
-
2003
- 2003-01-08 IL IL153846A patent/IL153846A/en active IP Right Grant
- 2003-03-28 US US10/401,032 patent/US7014847B2/en not_active Expired - Fee Related
-
2005
- 2005-10-21 US US11/255,849 patent/US7452723B2/en not_active Expired - Fee Related
-
2007
- 2007-05-30 US US11/809,195 patent/US7708987B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
IL153846A (en) | 2010-12-30 |
US7708987B2 (en) | 2010-05-04 |
IL153846A0 (en) | 2003-07-31 |
EP2027866A1 (de) | 2009-02-25 |
EP2016948A3 (de) | 2009-01-28 |
AR029839A1 (es) | 2003-07-16 |
JP2004505924A (ja) | 2004-02-26 |
NZ523509A (en) | 2004-11-26 |
EP1309334A2 (de) | 2003-05-14 |
MXPA03000859A (es) | 2004-04-05 |
WO2002011742A3 (en) | 2002-04-18 |
US20080075729A1 (en) | 2008-03-27 |
ZA200300411B (en) | 2004-01-26 |
CA2415750A1 (en) | 2002-02-14 |
US7014847B2 (en) | 2006-03-21 |
WO2002011742A2 (en) | 2002-02-14 |
DE60137631D1 (de) | 2009-03-26 |
ES2317921T3 (es) | 2009-05-01 |
AU7621801A (en) | 2002-02-18 |
EP1309334B1 (de) | 2009-02-11 |
MX358055B (es) | 2018-08-03 |
CA2415750C (en) | 2006-03-28 |
US6565831B1 (en) | 2003-05-20 |
EP2016948A2 (de) | 2009-01-21 |
BR0113128A (pt) | 2003-07-22 |
AU2001276218B8 (en) | 2006-08-24 |
US20060073166A1 (en) | 2006-04-06 |
US20030215443A1 (en) | 2003-11-20 |
AU2001276218B2 (en) | 2006-08-03 |
US7452723B2 (en) | 2008-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE422358T1 (de) | Kombinationstherapie mittels reovirus und anti- antireovirus antikörpern zur behandlung von ras- vermittelten, proliferativen erkrankungen | |
ATE400283T1 (de) | Reovirus zur behandlung von zellulären proliferativen erkrankungen | |
DE60335293D1 (de) | Pyrrolopyridazin-verbindungen und verwendungsverfahren dafür zur behandlung von proliferativen erkrankungen | |
ATE369133T1 (de) | Zur behandlung von schmerzen geeignete therapeutische mittel | |
DE60124302D1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
DE60138129D1 (de) | Apparat zur behandlung von zähnen | |
DE60023043D1 (de) | (S,S)-Reboxetin zur Behandlung von Inkontinenz | |
ATE275145T1 (de) | Chinazolinderivate zur behandlung von tumoren | |
ATE380548T1 (de) | Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie | |
DE60327622D1 (de) | Kombinierte antitachykardie - schrittmacher und hochspannungstherapie zur behandlung von ventrikulären arrhythmien | |
EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
ATE417602T1 (de) | Mittel zur behandlung von erkrankungen der speiseröhre | |
DE60035378D1 (de) | Gerät zur Behandlung von Bandscheiben | |
EA200600078A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
DE60032795D1 (de) | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren | |
DE60108857D1 (de) | Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren | |
DE60229959D1 (de) | Kombinationstherapie zur behandlung von krebs | |
ATE255894T1 (de) | Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen | |
DE60136477D1 (de) | Retinoide zur behandlung von emphysem | |
DE50013843D1 (de) | Arzneimittel zur behandlung von darmerkrankungen | |
DE50114605D1 (de) | No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz | |
DE60016047D1 (de) | Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten | |
ATE482707T1 (de) | 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen | |
DE50313329D1 (de) | 1-phenyl-2-dimethylaminomethylcyclohexanverbindungen zur therapie von depressiven symptomatiken, schmerz und inkontinenz | |
DE60130691D1 (de) | Indolderivate zur Behandlung von Erkrankungen des Zentralnervensystems |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |